Yoshie Morimoto

发表

Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

T. Kijima, K. Takayama, J. Uchino, 2022, Diagnostics.

Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study

T. Kijima, K. Takayama, J. Uchino, 2021, Oncoimmunology.

Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients

K. Takayama, J. Uchino, K. Morimoto, 2021, Journal of Cancer Research and Clinical Oncology.

The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study

K. Takayama, J. Uchino, M. Takeuchi, 2021, Frontiers in Oncology.

Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study

T. Kijima, K. Takayama, J. Uchino, 2021, Journal of Cancer Research and Clinical Oncology.

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study

K. Takayama, K. Morimoto, Tadaaki Yamada, 2021, Thoracic cancer.

Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review

K. Takayama, J. Uchino, Tadaaki Yamada, 2020, Journal of clinical medicine.

Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients

K. Takayama, J. Uchino, K. Morimoto, 2020, Medical Oncology.

Can the assessment of lymphocyte exhaustion serve as a prognostic predictor after lung cancer surgery?

J. Uchino, K. Morimoto, Yoshie Morimoto, 2020, Translational lung cancer research.

Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study

K. Takayama, Tadaaki Yamada, Shinsaku Tokuda, 2022, JTO clinical and research reports.

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study

S. Yano, K. Takayama, J. Uchino, 2021, Translational lung cancer research.

Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study

K. Takayama, J. Uchino, Tadaaki Yamada, 2021, Translational lung cancer research.

Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review

K. Takayama, J. Uchino, M. Fukui, 2020, Journal of clinical medicine.

Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab

K. Takayama, J. Uchino, Tadaaki Yamada, 2021, Internal medicine.

Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients

K. Takayama, J. Uchino, Tadaaki Yamada, 2021, Journal of Cancer Research and Clinical Oncology.

A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors.

O. Ukimura, K. Takayama, N. Katoh, 2022, International immunopharmacology.

Association of immune checkpoint inhibitors with respiratory infections: A review.

K. Takayama, J. Uchino, Tadaaki Yamada, 2020, Cancer treatment reviews.

Changes in serum transforming growth factor-beta concentration as a predictive factor for radiation-induced lung injury onset in radiotherapy-treated patients with locally advanced lung cancer

K. Takayama, Tadaaki Yamada, Y. Kaneko, 2021, Translational lung cancer research.

Concurrent hemoptysis and pulmonary embolism associated with lenvatinib therapy for unresectable thymic carcinoma: A case report

K. Takayama, Tadaaki Yamada, T. Yoshikawa, 2022, Current Problems in Cancer: Case Reports.

Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study

T. Kijima, K. Takayama, J. Uchino, 2021, Journal of Cancer Research and Clinical Oncology.

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial

K. Takayama, J. Uchino, M. Hibino, 2022, JTO clinical and research reports.

Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.

K. Takayama, Y. Iwasaki, Y. Kaneko, 2018, Anticancer research.

Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer.

M. Horinaka, T. Sakai, S. Yano, 2021, Cancer letters.

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells

M. Horinaka, T. Sakai, S. Yano, 2022, Cancer medicine.

HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features

M. Horinaka, T. Sakai, Ryohei Katayama, 2022, npj Precision Oncology.

K. Takayama, J. Uchino, K. Morimoto, 2021, Frontiers in Oncology.

Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells.

K. Takayama, O. Mazda, T. Kishida, 2018, Biochemical and biophysical research communications.

Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer.

T. Kijima, K. Takayama, J. Uchino, 2021, Lung cancer.

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC

K. Takayama, K. Azuma, Tadaaki Yamada, 2022, JTO clinical and research reports.

Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation

Nozomi Tani, Yoshie Morimoto, Takayuki Shimamoto, 2023, Cureus.

Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer

K. Takayama, Tadaaki Yamada, Shinsaku Tokuda, 2022, AntiCancer Research.